Cytokine-induced killer cells interact with tumor lysate-pulsed dendritic cells via CCR5 signaling.
暂无分享,去创建一个
J. Hong | S. Han | J. Kang | H. Lee | Ji Sung Kim | Boyeong Kim | E. J. Park | Ki Hwan Park | Youngsoo Kim | Yong Guk Kim
[1] Q. Qian,et al. The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors , 2015, Experimental Hematology & Oncology.
[2] Yan-chun Li,et al. Bioactivity of umbilical cord blood dendritic cells and anti-leukemia effect. , 2015, International journal of clinical and experimental medicine.
[3] C. Ji,et al. Immunomodulatory effect of DC/CIK combined with chemotherapy in multiple myeloma and the clinical efficacy. , 2015, International journal of clinical and experimental pathology.
[4] Liping Wang,et al. Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma. , 2015, Cancer letters.
[5] J. Hong,et al. Platycodon grandiflorum polysaccharide induces dendritic cell maturation via TLR4 signaling. , 2014, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[6] J. Gutkind,et al. Melanoma cell lysate induces CCR7 expression and in vivo migration to draining lymph nodes of therapeutic human dendritic cells , 2014, Immunology.
[7] Jian-ying Zhang,et al. Modification of chemokine receptor expression to enhance levels of trafficking receptors on autologous cytokine-induced killer cells derived from patients with colorectal cancer. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[8] C. Contag,et al. A killer choice for cancer immunotherapy , 2014, Immunologic Research.
[9] Y. Zou,et al. Manipulating the expression of chemokine receptors enhances delivery and activity of cytokine-induced killer cells , 2014, British Journal of Cancer.
[10] P. Kunda,et al. Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells, have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells. , 2013, Oncology reports.
[11] Y. Yun,et al. Decreased pain responses of C–C chemokine receptor 5 knockout mice to chemical or inflammatory stimuli , 2013, Neuropharmacology.
[12] J. Hong,et al. Activation of macrophages by polysaccharide isolated from Paecilomyces cicadae through toll-like receptor 4. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[13] J. Hong,et al. Adjuvant effect of a natural TLR4 ligand on dendritic cell-based cancer immunotherapy. , 2011, Cancer Letters.
[14] S. Beissert,et al. Structure and duration of contact between dendritic cells and T cells are controlled by T cell activation state , 2006, European journal of immunology.
[15] C. Moratz,et al. Rgs1 and Gnai2 regulate the entrance of B lymphocytes into lymph nodes and B cell motility within lymph node follicles. , 2005, Immunity.
[16] S. Zhang,et al. Enhanced antitumor immunity by murine cytokine activated T lymphocytes after cocultured with bone marrow derived dendritic cells pulsed with whole tumor lysates. , 2004, Leukemia research.
[17] Robert S Negrin,et al. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. , 2004, Blood.
[18] S. Henrickson,et al. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases , 2004, Nature.
[19] R. Negrin,et al. Studies of ex Vivo Activated and Expanded CD8+ NK-T Cells in Humans and Mice , 2002, Journal of Clinical Immunology.
[20] T. Sauerbruch,et al. Interactions Between Dendritic Cells and Cytokine-Induced Killer Cells Lead to an Activation of Both Populations , 2001, Journal of immunotherapy.
[21] I. Weissman,et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity , 1991, The Journal of experimental medicine.
[22] Jin Gao,et al. Combination of cytokine-induced killer and dendritic cells pulsed with antigenic α-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy. , 2016, Cytotherapy.
[23] C. Klein,et al. Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. , 2011, Blood.